Literature DB >> 30926062

The prognosis of head and neck squamous cell carcinoma related to immunosuppressive tumor microenvironment regulated by IL-6 signaling.

Ming-Shao Tsai1, Wen-Cheng Chen2, Chang-Hsien Lu3, Miao-Fen Chen4.   

Abstract

Evasion of immune surveillance is a significant factor in head and neck squamous cell carcinoma (HNSCC) carcinogenesis. IL-6 signaling is a critical mechanism for the induction of dysfunctional immune responses. In the present study, we examined the role of IL-6 in the prognosis of HNSCC regarding the immunosuppressive tumor microenvironment. We retrospectively analyzed the clinical outcomes of HNSCC patients and examined its correlation with the levels of IL-6 in tumors and circulating myeloid-derived suppressor cells (MDSCs) in peripheral blood. Furthermore, the relationships between IL and 6, programmed death ligand (PD-L1) expression, and immune response were examined in vitro and in vivo. Our data revealed that IL-6 overexpression was associated with the increased risk of developing disease failure and poor prognosis for HNSCC. The immunoreactivity of IL-6 in HNSCC specimens was positively linked to the staining of PD-L1 and the level of circulating MDSCs. By cellular and animal experiments, there were augmented radiation-induced increases in the expression of PD-L1 and the activation of MDSCs noted in IL-6-positive tumors. When IL-6 signaling was inhibited, the levels of PD-L1 and MDSC recruitment were significantly down-regulated. Furthermore, the neutrophil-to-lymphocyte ratio (NLR) was positively correlated with the levels of IL-6 and PD-L1 in tumor, and circulating MDSCs. In conclusion, IL-6 is a significant predictor of treatment outcome in HNSCC patients, and plays an important role in the induction of immunosuppressive tumor microenvironment mediated by increased MDSCs and PD-L1 expression. Furthermore, IL-6 combined with NLR can assist the clinician to make an informed decision regarding treatment options.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Head and neck cancer; IL-6; Immune; MDSC; PD-L1

Mesh:

Substances:

Year:  2019        PMID: 30926062     DOI: 10.1016/j.oraloncology.2019.02.027

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  23 in total

1.  Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.

Authors:  Sarah Greene; Yvette Robbins; Wojciech K Mydlarz; Angel P Huynh; Nicole C Schmitt; Jay Friedman; Lucas A Horn; Claudia Palena; Jeffrey Schlom; Dean Y Maeda; John A Zebala; Paul E Clavijo; Clint Allen
Journal:  Clin Cancer Res       Date:  2019-12-17       Impact factor: 12.531

2.  Effect of 1α,25-Dihydroxyvitamin D3 on the Radiation Response in Prostate Cancer: Association With IL-6 Signaling.

Authors:  Chun-Te Wu; Yun-Ching Huang; Wen-Cheng Chen; Miao-Fen Chen
Journal:  Front Oncol       Date:  2021-05-24       Impact factor: 6.244

Review 3.  Precision and Immunoprevention Strategies for Tobacco-Related Head and Neck Cancer Chemoprevention.

Authors:  Sara M Centuori; Carlos Caulin; Julie E Bauman
Journal:  Curr Treat Options Oncol       Date:  2021-05-15

4.  Immune Cell Infiltrates and Neutrophil-to-Lymphocyte Ratio in Relation to Response to Chemotherapy and Prognosis in Laryngeal and Hypopharyngeal Squamous Cell Carcinomas.

Authors:  Mario Sánchez-Canteli; Luis Juesas; Esther Redin; Alfonso Calvo; Fernando López; Aurora Astudillo; Luis M Montuenga; Juana M García-Pedrero; Juan P Rodrigo
Journal:  Cancers (Basel)       Date:  2021-04-25       Impact factor: 6.639

Review 5.  Importance of myeloid derived suppressor cells in cancer from a biomarker perspective.

Authors:  Suresh Gopi Kalathil; Yasmin Thanavala
Journal:  Cell Immunol       Date:  2020-12-31       Impact factor: 4.178

Review 6.  Clinical update on head and neck cancer: molecular biology and ongoing challenges.

Authors:  Elham Alsahafi; Katheryn Begg; Ivano Amelio; Nina Raulf; Philippe Lucarelli; Thomas Sauter; Mahvash Tavassoli
Journal:  Cell Death Dis       Date:  2019-07-15       Impact factor: 8.469

7.  On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy.

Authors:  Pablo Nenclares; Lucinda Gunn; Heba Soliman; Mateo Bover; Amy Trinh; Isla Leslie; Kee Howe Wong; Alan Melcher; Kate Newbold; Chris M Nutting; Derfel Ap Dafydd; Shreerang A Bhide; Kevin Harrington
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

Review 8.  Immune deserts in head and neck squamous cell carcinoma: A review of challenges and opportunities for modulating the tumor immune microenvironment.

Authors:  Janice L Farlow; J Chad Brenner; Yu L Lei; Steven B Chinn
Journal:  Oral Oncol       Date:  2021-07-01       Impact factor: 5.972

9.  Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells.

Authors:  Chen Zhu; Zhili Song; Anlai Wang; Srimathi Srinivasan; Guang Yang; Rita Greco; Joachim Theilhaber; Elvis Shehu; Lan Wu; Zhi-Yong Yang; Wilfried Passe-Coutrin; Alain Fournier; Yu-Tzu Tai; Kenneth C Anderson; Dmitri Wiederschain; Keith Bahjat; Francisco J Adrián; Marielle Chiron
Journal:  Front Immunol       Date:  2020-08-14       Impact factor: 7.561

10.  Radiotherapy-Induced Changes in the Systemic Immune and Inflammation Parameters of Head and Neck Cancer Patients.

Authors:  Katalin Balázs; Enikő Kis; Christophe Badie; Enikő Noémi Bogdándi; Serge Candéias; Lourdes Cruz Garcia; Iwona Dominczyk; Benjamin Frey; Udo Gaipl; Zsolt Jurányi; Zsuzsa S Kocsis; Eric Andreas Rutten; Géza Sáfrány; Piotr Widlak; Katalin Lumniczky
Journal:  Cancers (Basel)       Date:  2019-09-06       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.